Nombre del producto:7-Methoxy-1,1-dimethyl-3,4-dihydronaphthalen-2(1H)-one

IUPAC Name:7-methoxy-1,1-dimethyl-1,2,3,4-tetrahydronaphthalen-2-one

CAS:1865-83-4
Fórmula molecular:C13H16O2
Pureza:95%
Número de catálogo:CM140627
Peso molecular:204.27

Unidad de embalaje Stock disponible Precio($) Cantidad
CM140627-250mg in stock ƞư
CM140627-1g in stock ȎNJŢ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1865-83-4
Fórmula molecular:C13H16O2
Punto de fusión:-
Código de sonrisas:O=C1C(C)(C)C2=C(C=CC(OC)=C2)CC1
Densidad:
Número de catálogo:CM140627
Peso molecular:204.27
Punto de ebullición:
Nº Mdl:MFCD20274514
Almacenamiento:

Category Infos

Naphthalenes
Naphthalene is a hydrocarbon produced by the distillation of coal tar and is an aromatic white crystalline substance. Naphthalene is the most abundant component in coal tar. It is used as an insect repellant and insect fumigant. The compound is used in the manufacture of celluloid, dyes, hydrogenated naphthalenes, oil fumes, smokeless powders and synthetic resins.

Column Infos

Alectinib
Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products